IDA Ireland sets out long-term plan to shore up biopharma role

IDA Ireland has released a new whitepaper setting out how the country intends to strengthen its role as a global center for biopharmaceutical manufacturing. The report highlights stability, regulatory strength and a deep talent base as crucial advantages as companies navigate geopolitical shifts and rapid advances in technology.

Over the past decade, Ireland has attracted 15 billion euros (around $16 billion) in foreign direct investment, much of it directed at modern biologics and advanced-therapy facilities. The document arrives as Ireland’s life-sciences industry continues to expand, generating more than 116 billion euros in annual exports and employing over 50,000 people.